IRAK1 functional genetic variant affects severity of septic shock

Critical Care Medicine

Volumn 38, Issue 12, 2010, Pages 2287-2294

  Toubiana, Julie ^a,b   Courtine, Emilie ^b   Pène, Frédéric ^a,b,c   Viallon, Vivian ^c   Asfar, Pierre ^d   Daubin, Cédric ^e   Rousseau, Christophe ^b   Chenot, Claire ^b   Ouaaz, Fatah ^b   Grimaldi, David ^a,b   Cariou, Alain ^a,c   Chiche, Jean Daniel ^a,b,c   Mira, Jean Paul ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CNRS   (France)

^c Assistance Publique Hôpitaux de Paris ^*  (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

ALI; genetic susceptibility; IRAK1; mortality; polymorphism; septic shock

Indexed keywords

ACTIVATED PROTEIN C; HYDROCORTISONE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; NORADRENALIN;

ACUTE LUNG INJURY; ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CAUCASIAN; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; FEMALE; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; SCORING SYSTEM; SEPTIC SHOCK; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

EID: 78650306225     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181f9f9c7     Document Type: Article

References (53)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001: 29:1303-1310
2. Annane D, Bellissant E, Cavaillon JM: Septic shock. Lancet 2005; 365:63-78
3. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554
4. Takeuchi O, Hoshino K, Kawai T, et al: Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity 1999; 11:443-451
5. Aderem A, Ulevitch RJ: Toll-like receptors in the induction of the innate immune response. Nature 2000; 406:782-787
6. Hotta N, Ichiyama T, Shiraishi M, et al: Nuclear factor-kappaB activation in peripheral blood mononuclear cells in children with sepsis. Crit Care Med 2007; 35:2395-2401
7. Arnalich F, Garcia-Palomero E, Lopez J, et al: Predictive value of nuclear factor kappaB activity and plasma cytokine levels in patients with sepsis. Infect Immun 2000; 68:1942-1945
8. Texereau J, Chiche JD, Taylor W, et al: The importance of Toll-like receptor 2 polymorphisms in severe infections. Clin Infect Dis 2005; 41(Suppl 7):S408-415
9. Dahmer MK, Randolph A, Vitali S, et al: Genetic polymorphisms in sepsis. Pediatr Crit Care Med 2005; 6:S61-73
10. Imahara SD, O'Keefe GE: Genetic determinants of the inflammatory response. Curr Opin Crit Care 2004; 10:318-324
11. Wunderink RG, Waterer GW: Genetics of sepsis and pneumonia. Curr Opin Crit Care 2003; 9:384-389
12. Holmes CL, Russell JA, Walley KR: Genetic polymorphisms in sepsis and septic shock: Role in prognosis and potential for therapy. Chest 2003; 124:1103-1115
13. Lorenz E, Mira JP, Frees KL, et al: Relevance of mutations in the TLR4 receptor in patients with Gram-negative septic shock. Arch Intern Med 2002; 162:1028-1032
14. Brenmoehl J, Herfarth H, Gluck T, et al: Genetic variants in the NOD2/CARD15 gene are associated with early mortality in sepsis patients. Intensive Care Med 2007; 33:1541-1548
15. Henckaerts L, Nielsen KR, Steffensen R, et al: Polymorphisms in innate immunity genes predispose to bacteremia and death in the medical intensive care unit. Crit Care Med 2009; 37:192-201, e191-e193
16. Khor CC, Chapman SJ, Vannberg FO, et al: A malfunctional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 2007; 39:523-528
17. Chapman SJ, Khor CC, Vannberg FO, et al: IkappaB genetic polymorphisms and invasive pneumococcal disease. Am J Respir Crit Care Med 2007; 176:181-187
18. Arcaroli J, Silva E, Maloney JP, et al: Variant IRAK-1 haplotype is associated with increased nuclear factor-kappaB activation and worse outcomes in sepsis. Am J Respir Crit Care Med 2006; 173:1335-1341
19. Akira S: Toll-like receptor signaling. J Biol Chem 2003; 278:38105-38108
20. Verdrengh M, Thomas JA, Hultgren OH: IL-1 receptor-associated kinase 1 mediates protection against Staphylococcus aureus infection. Microbes Infect 2004; 6:1268-1272
21. Dellinger RP, Carlet JM, Masur H, et al: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873
22. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: The ACCP/SCCM Consensus Conference Committee American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-1655
23. Brun-Buisson C, Doyon F, Carlet J, et al: Incidence, risk factors, and outcome of severe sepsis and septic shock in adults: A mul-ticenter prospective study in intensive care units French ICU Group for Severe Sepsis. JAMA 1995; 274:968-974
24. Schoenfeld DA, Bernard GR: Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med 2002; 30:1772-1777
25. Ekstrom CT: Multipoint linkage analysis of quantitative traits on sex-chromosomes. Genet Epidemiol 2004; 26:218-230
26. Zheng G JJ, Zhang C, Geller NL: Testing association for markers on the X chromosome. Genet Epidemiol 2007; 31:834-843
27. Manolio TA, Collins FS: The HapMap and genome-wide association studies in diagnosis and therapy. Annu Rev Med 2009; 60:443-456
28. Lohmueller KE, Pearce CL, Pike M, et al: Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003; 33:177-182
29. Alcais A, Alter A, Antoni G, et al: Stepwise replication identifies a low-producing lympho-toxin-alpha allele as a major risk factor for early-onset leprosy. Nat Genet 2007; 39: 517-522
30. Ardissino D, Mannucci PM, Merlini PA, et al: Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 1999; 94:46-51
31. Zwicker JI, Peyvandi F, Palla R, et al: The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor mul-timer size. Blood 2006; 108:1280-1283
32. Kathiresan S, Voight BF, Purcell S, et al: Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 2009; 41:334-341
33. Ware LB, Matthay MA: The acute respiratory distress syndrome. N Engl J Med 2000; 342: 1334-1349
34. Swantek JL, Tsen MF, Cobb MH, et al: IL-1 receptor-associated kinase modulates host responsiveness to endotoxin. J Immunol 2000; 164:4301-4306
35. Kawagoe T, Sato S, Matsushita K, et al: Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nat Immunol 2008; 9:684-691
36. Song KW, Talamas FX, Suttmann RT, et al: The kinase activities of interleukin-1 receptor associated kinase (IRAK)-1 and 4 are redundant in the control of inflammatory cy-tokine expression in human cells. Mol Immunol 2009; 46:1458-1466
37. Cavaillon JM, Adib-Conquy M, Fitting C, et al: Cytokine cascade in sepsis. Scand J Infect Dis 2003; 35:535-544
38. Gottipati S, Rao NL, Fung-Leung WP: IRAK1: A critical signaling mediator of innate immunity. Cell Signal 2008; 20:269-276
39. Liu G, Tsuruta Y, Gao Z, et al: Variant IL-1 receptor-associated kinase-1 mediates increased NF-kappa B activity. J Immunol 2007; 179:4125-4134
40. Jensen LE, Whitehead AS: IRAK1b, a novel alternative splice variant of interleukin-1 receptor-associated kinase (IRAK), mediates interleukin-1 signaling and has prolonged stability. J Biol Chem 2001; 276: 29037-29044
41. Tidswell M, Tillis W, Larosa SP, et al: Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 2010; 38:72-83
42. Wang Z, Wesche H, Stevens T, et al: IRAK-4 inhibitors for inflammation. Curr Top Med Chem 2009; 9:724-737
43. Sperry JL, Minei JP: Gender dimorphism following injury: Making the connection from bench to bedside. J Leukoc Biol 2008; 83:499-506
44. Moss M, Mannino DM: Race and gender differences in acute respiratory distress syndrome deaths in the United States: An analysis of multiple-cause mortality data (1979-1996). Crit Care Med 2002; 30: 1679-1685
45. Wichmann MW, Inthorn D, Andress HJ, et al: Incidence and mortality of severe sepsis in surgical intensive care patients: the influence of patient gender on disease process and outcome. Intensive Care Med 2000; 26: 167-172
46. Karlberg J, Chong DS, Lai WY: Do men have a higher case fatality rate of severe acute respiratory syndrome than women do? Am J Epidemiol 2004; 159:229-231
47. Diodato MD, Knoferl MW, Schwacha MG, et al: Gender differences in the inflammatory response and survival following haemorrhage and subsequent sepsis. Cytokine 2001; 14:162-169
48. Imahara SD, Jelacic S, Junker CE, et al: The influence of gender on human innate immunity. Surgery 2005; 138:275-282
49. Moxley G, Posthuma D, Carlson P, et al: Sexual dimorphism in innate immunity. Arthritis Rheum 2002; 46:250-258
50. Hattersley AT, McCarthy MI: What makes a good genetic association study? Lancet 2005; 366:1315-1323 51.
51. Kimman TG, Banus S, Reijmerink N, et al: Association of interacting genes in the tolllike receptor signaling pathway and the antibody response to pertussis vaccination. PLoS One 2008; 3:e3665
52. Xavier RJ, Rioux JD: Genome-wide association studies: A new window into immune-mediated diseases. Nat Rev Immunol 2008; 8:631-643
53. Angus DC, Burgner D, Wunderink R, et al: The PIRO concept: P is for predisposition. Crit Care 2003; 7:248-251